Therapeutic mAbs against disease-specific targets

Alethia Biotherapeutics develops monoclonal antibody therapeutics to novel clinically relevant targets identified using its patented STAR discovery technology. The Company is currently focusing on cancer-induced bone loss, ovarian cancer and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.

Events


January 10 - 12, 2012

Alethia Biotherapeutics to present at the Biotech Showcase 2012 on Tuesday, January 10 at 3:30 PM  at the Parc 55 Wyndham San Francisco – Union Square, San Francisco, USA.


Yves Cornellier and Mario Filion  will be in attendance.


October 31 - November 2, 2011

Alethia Biotherapeutics to be part of the BIO Europe 17th Annual International Partnering Conference in Dusseldorf, Germany


Yves Cornellier and Mario Filion  will be in attendance.


September 16 -20, 2011

Alethia Biotherapeutics to present at the Annual ASBMR Meeting. Dr. Matthew Stuible will present data on a new bone antiresoprtive: Targeting of the DAP12-associated, Osteoclast-specific Receptor Siglec-15 by Antibody 25E9 Inhibits Differentiation and Resorption Activity.

Oral presentation #1187, September 19, 2:45 PM; San Diego Convention Center, San Diego, CA


Gilles Tremblay and Matthew Stuible will be in attendance.



News


November 9, 2011

Alethia Biotherapeutics announces promising in vivo results its EMT inhibitor AB-16B5 and issuance of a patent for the role of secreted clusterin in EMT


September 17, 2011

Dr. Matthew Stuible receives an ASBMR young investigator award for his abstract entitled “Targeting of the DAP12-associated, Osteoclast-specific Receptor Siglec-15 by Antibody 25E9 Inhibits Differentiation and Resorption Activity”


August 8, 2011

Alethia Biotherapeutics Announces Issuance of its Second Therapeutic Target Patent Stemming from its Proprietary Target Discovery Platform


June 3, 2011

Alethia Biotherapeutics announces partnership with Goodwin Biotechnologies for manufacturing of its monoclonal antibody, AB-16B5, an inhibitor of EMT for the treatment of cancer


May 26, 2011

Alethia Biotherapeutics announces issuance of its first therapeutic target patent emanating from its proprietary target discovery platform



More news

















© 2012 Alethia Biotherapeutics Inc. All rights reserved.

Best viewed with Firefox, Internet Explorer 7 and Safari